The marketing of Cholurso 500 in Great Britain marks the beginning of the internationalisation of this product, which, until now, had only been sold on the French market.
 Alverine 60 marks another milestone for our MeteoSpasmyl franchise, achieved through the first marketing of Alverine not combined with simeticone.
Still small progress in terms of turnover, but a huge one for Mayoly Spindler in terms of willingness of presence and ambition across the channel to conquer a British market that is very attractive for our products.

The launch of The 15th edition of the AGA ‘à la Française’ (American Gastroenterology Association) took place on 17 June 2016 in Paris.
Over a hundred French gastroenterologists, as well as gastroenterologists from Algeria, Tunisia, Morocco and Lebanon, attended the event.

During this event, videos analysing major AGA communications and interviews with opinion leaders from around the world were broadcast. Discussions on these advances then fed debates.

This year Doctor Hervé HAGEGE once again coordinated and moderated the filming sessions with Professor Benoît COFFIN, Professor Jean-Christophe SAURIN, Doctor Geoffroy VANBIERVLIET and Professor Matthieu ALLEZ.

There was a new record this year for the 15th edition: the videos and interviews were conducted, filmed and edited, and the debates held with our expert gastroenterologist reporters, in just two weeks, providing AGA ‘à la Française’ attendees with a sneak peek at the latest information.

Also new this year, a mobile app was created in order to facilitate discussions among attendees.

Finally, all of the videos and discussions from the AGA ‘à la Française’ will soon be available on a dedicated platform in order to share this consolidation effort with as many people as possible.

The AGA ‘à la Française’ strongly confirmed the role of Laboratoires Mayoly Spindler as a benchmark company in the field of Gastroenterology.

Stéphane Thiroloix, new Polepharma President
Stéphane Thiroloix, CEO of Mayoly Spindler, an independent French and international pharmaceutical company and benchmark company in the field of gastroenterology and dermocosmetics, was elected President on Monday, 4 July 2016 by Polepharma’s Board of Directors.

He succeeds Guillaume Clément, President of LEO Pharma France, after three years of service.

Stéphane Thiroloix graduated from the École des Hautes Études Commerciales (HEC) [Paris Business School] and began his career at Roussel Uclaf (now Sanofi), where, for 11 years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.

He continued his career at SmithKline Beecham (GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President, Europe, Business Development and Marketing Alliances.

From 2002 to 2007, he was Vice-President of French Operations and then became Vice-President, Europe, and General Manager, France, at Bristol-Myers Squibb.

In 2007, he joined the executive committee at the Ipsen Group, a global biopharmaceutical company headquartered in France, as Executive VP, where he was in charge of Corporate Development (Business dDt and Legal Affairs, Pre-clinical and Clinical Development, Regulatory Affairs).

Before joining Laboratoires Mayoly Spindler, Stéphane Thiroloix had been working since 2011 as President, Europe, Canada, Japan and Australia, of the Advanced Surgical Devices (ASD) Division at Smith & Nephew.

Polepharma press contact: Caroline VILLEDIEU – 02 37 20 24 24

Mayoly Spindler press contact : Pascal FRUIT – 01 34 80 55 75

Cosmoprof North America,  the leading B2B beauty and cosmetics trade show, took place, this year, in Las Vegas.

The exhibition welcomed 1,000 exhibitors and attracted around 30,000 visitors from all over the world.

Our laboratory participated as an exhibitor with the aim of developing awareness of our brand, Topicrem, in the Americas, even though our products are preparing to conquer Canada before the end of the year.


Chophyshot®, your solution to take during periods of overeating

Chophyshot® is an artichoke-based dietary supplement with sweeteners to be taken during periods of festive overindulgence.
Thanks to its compact size containing a single daily dose, you can easily take this 10-ml bottle with you wherever you go.

Chophyshot® has been developed by our Research and Development teams in Chatou. Made from artichoke (11%), it is sugar-free and has an orange and grapefruit flavour.

Chophyshot®  should be taken once a day during periods of overeating.

Chophyshot® will be available in pharmacies from October 2016.
Recommended Retail Price: €1.50

Alcohol 2.6% vol.
Chophyshot® is a dietary supplement to be taken during periods of overeating. This product should not be used as a substitute for a varied diet.
Eat at least five portions of fruit and vegetables a day to stay healthy.
Chophyshot® must not be used by pregnant or breastfeeding women.
It is not advisable to exceed the recommended daily dose (a single daily dose).

Discover it